The Million Women Study: A licence to kill other investigations?

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 113, Issue 1, 2004, Pages 3-5

  Van Der Mooren, M J ^a   Kenemans, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast Cancer; Postmenopausal Hormone Therapy

Indexed keywords

ESTROGEN; PROGESTERONE; TIBOLONE;

ASSOCIATION; BREAST CARCINOMA; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; FEMALE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; LONG TERM CARE; MEDICAL PROFESSION; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RISK ASSESSMENT; SUMMER; TREATMENT OUTCOME;

EID: 1442359961     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2003.12.001     Document Type: Editorial

References (20)

1. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. The Lancet 2003;362:419-27.
2. Lagro-Janssen T., Rosser W.W., van Weel C. Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces. Commentary. The Lancet. 362:2003;414-415.
3. The Million Women Study Collaborative Group. The million women study: design and characteristics of the study population. Breast Cancer Res 1991;1:73-80.
4. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. Cancer incidence in five continents, vol. VIII. IARC Scientific Publications No. 155. Lyon: IARC; 2002.
5. Million Women Study Collaborators. Patterns of use of hormone replacement therapy on one million women in Britain, 1996-2000. Br J Obstet Gynaecol 2002;109:1319-30.
6. Lundstrom E., Christow A., Kersemaekers W., Svane G., Azavedo E., Soderqvist G.et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am. J. Obstet. Gynecol. 186:2002;717-722.
7. Persson I., Weiderpass E., Bergkvist L., Bergstrom R., Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Contr. 10:1999;253-260.
8. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:2000;485-491.
9. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int. J. Cancer. 81:1999;339-344.
10. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92:2000;328-332.
11. Chen C.L., Weiss N.S., Newcomb P., Barlow W., White E. Hormone replacement therapy in relation to breast cancer. JAMA. 287:2002;734-741.
12. Newcomb P.A., Titus-Ernstoff L., Egan K.M., Trentham-Dietz A., Baron J.A., Storer B.E.et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 11:2002;593-600.
13. Weiss L.K., Burkman R.T., Cushing-Haugen K.L., Voigt L.F., Simon M.S., Daling J.R.et al. Hormone replacement therapy regimens and breast cancer risk. Obstet. Gynecol. 100:2002;1148-1158.
14. Li C.I., Malone K.E., Porter P.L., Weiss N.S., Tang M.T., Cushing-Haugen K.L.et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 289:2003;3254-3263.
15. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. The Lancet 1997;350:1047-59.
16. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D.et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized trial. JAMA. 289:2003;3243-3253.
17. Hulley S., Furberg C., Barret-Connor E., Cauley J., Grady D., Haskell W.et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 288:2002;58-66.
18. Allen D.S., de Vries C.S., Farmer R.D.T. Pharmaceutical content and regimen of hormone replacement therapy and risk of breast cancer. Pharmacoepidemiol. Drug Safety. 11(Suppl. 1):2002;296.
19. Wertheimer M.D., Costanza M.E., Dodson T.F., D'Orsi C., Pastides H., Zapka J.G. Increasing the effort toward breast cancer detection. JAMA. 255:1986;1311-1315.
20. Nanda K., Bastian L.A., Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am. J. Obstet. Gynecol. 186:2002;325-334.